Ponatinib Treatment in CML and Ph plus ALL Patients: Real-Life Data from the Czech Registries

被引：0
|
作者：
Koritakova, Eva
Doubek, Michael
Faber, Edgar
Zackova, Daniela
Horacek, Jan M.
Belohlavkova, Petra
Cmunt, Eduard
Folber, Frantisek
Jindra, Pavel
Klamova, Hana
Koristek, Zdenek
Stejskal, Lukas
Szotkowski, Tomas
Salek, Cyril
Kellnerova, Renata
Chrapava, Marika
机构：
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5905
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Ponatinib (Iclusig) for CML and Ph plus ALL
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1424): : 71 - 72
  • [2] Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Data from a Nationwide Belgian Registry
    Devos, Timothy
    Havelange, Violaine
    Theunissen, Koen
    Meers, Stef
    Benghiat, Fleur Samantha
    Gadisseur, Alain
    Vanstraelen, Gaetan
    Andre, Marc
    Bailly, Benjamin
    Granacher, Nikki
    Lewalle, Philippe
    De Becker, Ann
    Van Eygen, Koen
    Lejeune, Marie
    Deeren, Dries
    Nifosi, Gianfilippo
    Triffet, Agnes
    Vrelust, Inge
    Bekaert, Julie
    Beck, Michael
    Selleslag, Dominik
    BLOOD, 2019, 134
  • [3] Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph plus ALL
    Kawano, Noriaki
    Kimura, Shinya
    Miura, Masatomo
    Tochigi, Taro
    Nakaike, Takashi
    Yamashita, Kiyoshi
    Mashiba, Koichi
    Kikuchi, Ikuo
    Takahashi, Naoto
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (04) : 509 - 516
  • [4] Efficacy and Safety of Ponatinib in CML and Ph plus ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry
    Devos, Timothy
    Theunissen, Koen
    Benghiat, Fleur Samantha
    Gadisseur, Alain
    Meers, Stef
    Selleslag, Dominik
    Vanstraelen, Gaetan
    Zachee, Pierre
    Andre, Marc
    Lewalle, Philippe
    Janssen, Mia
    Schots, Rik
    Van Eygen, Koen
    Kentos, Alain
    Lejeune, Marie
    Triffet, Agnes
    Vrelust, Inge
    Kuipers, Carolina
    Havelange, Violaine
    BLOOD, 2018, 132
  • [5] Ponatinib: An oral tyrosine kinase inhibitor for treatment of CML and Ph plus ALL
    Feret, Brett
    FORMULARY, 2013, 48 (05) : 169 - 170
  • [6] Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL
    Noriaki Kawano
    Shinya Kimura
    Masatomo Miura
    Taro Tochigi
    Takashi Nakaike
    Kiyoshi Yamashita
    Koichi Mashiba
    Ikuo Kikuchi
    Naoto Takahashi
    International Journal of Hematology, 2021, 114 : 509 - 516
  • [7] Ponatinib: hope for patients with CML or Ph-positive ALL?
    Yaqub, Farhat
    LANCET ONCOLOGY, 2013, 14 (13): : E588 - E588
  • [8] Real-life rates of disease monitoring in clinical practice in europe:: The "Unmet needs in CML and Ph plus ALL" (UNIC) study
    Morra, Enrica
    Michallet, Mauricette
    Steegmann, Juan
    Costa, David Marin
    Ossenkoppele, Gert
    Verhoef, Gregor
    Kuehr, Thomas
    Bjoereman, Mats
    Paga, Cosimo
    Cohen, Carine
    Villanueva, Isidro
    Halkin, Veronique
    Intorcia, Michele
    Cerri, Karin
    BLOOD, 2007, 110 (11) : 582A - 583A
  • [9] Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study
    Abulafia, Adi Shacham
    Raanani, Pia
    Lavie, David
    Volchek, Yulia
    Ram, Ron
    Hellman, Ilana
    Shargian, Liat
    Gourevietch, Anna
    Chubar, Evgeni
    Ratzon, Roy
    Rozovski, Uri
    BLOOD, 2017, 130
  • [10] A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients
    Luciano, Luigia
    Specchia, Giorgina
    Martino, Bruno
    Accurso, Vincenzo
    Santoro, Marco
    Malato, Alessandra
    Sgherza, Nicola
    Pizzuti, Michele
    Stagno, Fabio
    Musto, Pellegrino
    Guarini, Attilio
    De Gregorio, Fiorenza
    Basile, Santina
    Pane, Fabrizio
    BLOOD, 2017, 130
12345